Home - Medical Policies - Alabama
Draft Provider-Administered Drug Policies (Excluding Oncology) - Blue Advantage
To ensure that the development of Blue Cross and Blue Shield of Alabama provider-administered policies occurs through an open, collaborative process, we welcome physicians and other providers to submit comments about pharmacy policies that are in the draft stage.
Note: Coverage is subject to member's specific benefits. Group specific policies will supersede these policies when applicable. Please refer to member's benefit plan.
Current Draft Policies
Draft provider-administered drug policies (excluding oncology) are listed below in alphabetical order. If there are no policies listed, then no policies are in draft status.
How to Submit Comments
We invite our participating physicians and other providers to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We receive comments for 45 days from the posting date listed on the document.
Participating providers can comment on draft policies two ways:
- Comment on Draft Pharmacy Policy
- Send comments by fax to 205-733-6471 using the Drug Policy Comments Coversheet
|PH-0350||Luxturna (voretigene neparvovec-rzyl)|
|PH-0346||Mepsevii (vestronidase alfa-vjbk)|